SRR8942954
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.440
- MITOTIC_SPINDLE+0.260
- ESTROGEN_RESPONSE_LATE+0.220
- UV_RESPONSE_UP+0.210
- TGF_BETA_SIGNALING+0.200
- PEROXISOME+0.190
- OXIDATIVE_PHOSPHORYLATION+0.170
- P53_PATHWAY+0.170
- PROTEIN_SECRETION+0.170
Top 10 suppressed
- APICAL_SURFACE-0.280
- KRAS_SIGNALING_DN-0.270
- IL6_JAK_STAT3_SIGNALING-0.260
- WNT_BETA_CATENIN_SIGNALING-0.250
- HEDGEHOG_SIGNALING-0.230
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.220
- INFLAMMATORY_RESPONSE-0.220
- ALLOGRAFT_REJECTION-0.210
- HYPOXIA-0.200
- INTERFERON_ALPHA_RESPONSE-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A2-A25E-01A-11R-A169-07 | — | B | 0.794 |
| 2 | R125 | — | — | 0.778 |
| 3 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.773 |
| 4 | TCGA-BH-A1FJ-01A-11R-A13Q-07 | — | B | 0.758 |
| 5 | TCGA-A2-A0ER-01A-21R-A034-07 | — | B | 0.758 |
| 6 | TCGA-A8-A095-01A-11R-A00Z-07 | — | B | 0.754 |
| 7 | SJEPD030854_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.754 |
| 8 | TCGA-A2-A1G4-01A-11R-A13Q-07 | — | B | 0.754 |
| 9 | SRR12202419 | — | — | 0.751 |
| 10 | TCGA-AR-A0U3-01A-11R-A109-07 | — | B | 0.744 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.170 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.170 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.130 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.110 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |